NCT05494723View on ClinicalTrials.gov

Safety and Efficacy of YB-1113 in Treatment of POI

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

January 9, 2026

Primary Completion Date

July 9, 2027

Study Completion Date

August 30, 2028

Conditions

POI

Interventions

DRUG

YB-1113

Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)

Sponsors

Lead Sponsor

Bright Cell, Inc.

All Listed Sponsors

lead

Bright Cell, Inc.

INDUSTRY